NBSE News and Press, NeuBase Therapeutics Inc. From 04/21/21

NeuBase Therapeutics (NBSE) trades 6.7% down after hours on commencing an underwritten public offering of shares; underwriters granted 30-day option to purchase up to an additional 15% of the shares.Offer size, terms have not been disclosed.Net proceeds to be used for general c...

NeuBase Therapeutics Inc. (NASDAQ:NBSE) traded today at a new 52-week low of $5.74. So far today approximately 188,000 shares have been exchanged, as compared to an average 30-day volume of 216,000 shares. NeuBase Therapeutics Inc. (NASDAQ:NBSE) has potential upside of 18.5% based on a c...

NeuBase Therapeutics Inc. (NASDAQ:NBSE) traded today at a new 52-week low of $5.77. So far today approximately 188,000 shares have been exchanged, as compared to an average 30-day volume of 216,000 shares. NeuBase Therapeutics Inc is a pre-clinical stage bio-pharmaceutical company. It is...

NeuBase Therapeutics Inc. (NASDAQ:NBSE) traded today at a new 52-week low of $5.76. So far today approximately 188,000 shares have been exchanged, as compared to an average 30-day volume of 216,000 shares. NeuBase Therapeutics Inc is a pre-clinical stage bio-pharmaceutical company. It is...

HOUSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc., (Coya™), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune disease...

PITTSBURGH, April 08, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that it will ho...

David Einhorn's 13F stock portfolio value increased from $1.22B to $1.66B this quarter. Greenlight increased Atlas Air Worldwide, Teck Resources, and Resideo Technologies while reducing AerCap Holdings, Chemours, and NCR Corp. during the quarter. The largest three positions are at...

The following slide deck was published by NeuBase Therapeutics, Inc. in conjunction with this event. For further details see: Neubase Therapeutics (NBSE) Investor Presentation - Slideshow

PITTSBURGH, March 16, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today an oral presentation at th...

PITTSBURGH, March 09, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, ...